
Olympus Announces Launch of Single-Use Hemostasis Clip
Olympus, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced today the launch of a new hemostasis clip to help meet the needs of GI endoscopists. Olympus Corporation of the Americas reports.
The Retentia™ HemoClip provides 360° rotation and an intuitive one-step deployment, offering control over placement with three different sizes to accommodate a variety of closure applications.1 It will launch in the U.S, with plans for further global expansion.
The Retentia™ HemoClip offers the following benefits:
- Arm lengths of 9mm, 12mm, and 16mm to accommodate a variety of closure applications1
- A short tail length which helps with visualization of the target site, potentially facilitating the placement of multiple clips compared to long tail lengths1
- Sheath markings that are designed to aid in insertion and extraction1
- An intuitive handle design which enables the clip to be deployed in a single step1.
Performing hemostasis within the GI tract is a technically demanding procedure and use of hemostatic clips and associated devices may result in patient injury including but not limited to inflammatory reaction, infection, bleeding and perforation.
“The Retentia™ HemoClip is another example of Olympus’ commitment to understanding the needs of clinicians and addressing them, and for this reason among others, we are excited to bring this solution to the market,” said Mike Callaghan, Global VP and General Manager for EndoTherapy, Olympus Corp. of the Americas. “As procedural needs within GI endoscopy continue to evolve, so too must our solutions. Features like ease in deployment and a broad range of size options have become imperative for procedure success, and we’re proud to deliver on these improvements for GI endoscopists.”
The Retentia™ HemoClip is part of a comprehensive Olympus EndoTherapy portfolio that provides physicians with advanced solutions for procedures such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD).
EMR and ESD2 are techniques for removing cancerous or other abnormal tissues from the digestive tract. Olympus’ endoscopic portfolio includes devices such as electrosurgical knives, and hemostatic forceps that provide targeted monopolar coagulation. The portfolio also includes technology to help detect and control gastrointestinal bleeding in combination with conventional techniques such as clips.
Hemostasis is an important concern for GI physicians, and the Retentia™ HemoClip reflects Olympus’ continued focus on solving the challenge of bleeding during endoscopic procedures. Olympus’ Red Dichromatic Imaging (RDI™) technology, a feature of the EVIS X1™ endoscopy system, helps improve the visibility of bleeding points within the mucosa and enhances the visibility of deep blood vessels compared to white light.3 RDI™ technology is not intended to replace histopathological sampling as a means of diagnosis. In addition, EndoClot® Polysaccharide Hemostatic Spray (PHS) is a powder hemostat indicated for use, in combination with other conventional techniques like clips, to control bleeds.
Visit the gastroenterology or hemostasis product pages for more information about the entire Olympus GI portfolio.
As a leading medical technology company, Olympus uses medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures with the goal of improving clinical outcomes, reducing overall costs, and enhancing the quality of life for patients. Olympus’ Medical portfolio includes, but is not limited to, endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of EndoTherapy devices.
1 Data on File with Yangzhou Fartley Medical Instrument Technology Co., Ltd.
2 ESD is technically demanding, and improper use may result in patient injury, bleeding and/or perforation.
3 Data on file with Olympus (D00489968)
-
May 12, 2025, 06:16Continuing to improve care for Haemophilia and Bleeding Disorders - HCPA
-
May 12, 2025, 05:50Brian O Mahony: Sanofi and Sobi Have Renewed Their Commitment to the WFH Humanitarian Aid Programme
-
May 10, 2025, 16:42Irish Haemophilia Society Opens Registration for Parent and Child Event at Lilliput Adventure Centre
-
May 10, 2025, 16:12Haemnet Launches 2025 Haemcast Series Featuring Terence O'Rourke
-
May 10, 2025, 14:50There was no treatment at all – Nurbek Rozaliev
-
May 10, 2025, 10:31Brian O Mahony Raises Concerns Over Lack of Evidence in Moderate Hemophilia Treatment
-
May 10, 2025, 09:04Prevalence of Iron Deficiency and Iron-Deficiency Anemia in US Females Aged 12-21 Years
-
May 9, 2025, 07:19How do the mechanical properties of a venous thrombus change over time? - VascularMedicine
-
May 9, 2025, 07:04Nick Murray Shares Nationwide Data on Thrombectomy Outcomes in CVST
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
May 21, 2025, 10:41Thrombosis Canada Opens Registration for 2025 Annual Education Conference
-
May 12, 2025, 08:00BSH-Haematology Announces Newly Elected Members on The Trustee Board
-
May 12, 2025, 07:37Laura Miller Highlights Supportive Care Workshop at BSH 2025
-
May 12, 2025, 06:06Mary Cushman: Wonderful Memory From ISTH 2025
-
May 11, 2025, 10:29Clive Smith: First talk I’ve attended about haemophilia care and AI